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Abstract
Background: In this era of molecular targeting therapy when various systematic treatments can be selected,
prognostic biomarkers are required for the purpose of risk-directed therapy selection. Numerous reports of various
malignancies have revealed that 18-Fluoro-2-deoxy-D-glucose (
18F-FDG) accumulation, as evaluated by positron
emission tomography, can be used to predict the prognosis of patients. The purpose of this study was to evaluate
the impact of the maximum standardized uptake value (SUVmax) from 18-fluoro-2-deoxy-D-glucose positron
emission tomography/computed tomography (
18F-FDG PET/CT) on survival for patients with advanced renal cell
carcinoma (RCC).
Methods: A total of 26 patients with advanced or metastatic RCC were enrolled in this study. The FDG uptake of
all RCC lesions diagnosed by conventional CT was evaluated by
18F-FDG PET/CT. The impact of SUVmax on patient
survival was analyzed prospectively.
Results: FDG uptake was detected in 230 of 243 lesions (94.7%) excluding lung or liver metastases with diameters
of less than 1 cm. The SUVmax of 26 patients ranged between 1.4 and 16.6 (mean 8.8 ± 4.0). The patients with
RCC tumors showing high SUVmax demonstrated poor prognosis (P = 0.005 hazard ratio 1.326, 95% CI 1.089-
1.614). The survival between patients with SUVmax equal to the mean of SUVmax, 8.8 or more and patients with
SUVmax less than 8.8 were statistically different (P = 0.0012). This is the first report to evaluate the impact of
SUVmax on advanced RCC patient survival. However, the number of patients and the follow-up period were still
not extensive enough to settle this important question conclusively.
Conclusions: The survival of patients with advanced RCC can be predicted by evaluating their SUVmax using
18F-
FDG-PET/CT.
18F-FDG-PET/CT has potency as an “imaging biomarker” to provide helpful information for the clinical
decision-making.
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Renal cell carcinoma (RCC) accounts for 3% of all adult
cancers [1]. Approximately 30% of patients are diag-
nosed with metastases and an additional 20-40% of
patients develop metastases after radical nephrectomy
with curative intent [2,3]. The outcome of patients with
metastatic RCC is poor, with a median survival time of
10 to 21 months [4,5]
Classical cytokine therapies have been the only sys-
tematic treatments available for advanced RCC for a
long time [6-9]. The oncogenic mechanism of RCC has
been elucidated and agents that target relevant biologi-
cal pathways have been investigated. Multiple tyrosine
kinase inhibitors (multiple TKIs) targeting vascular
endothelial growth factor receptor (VEGFR) such as
sunitinib and sorafenib have revolutionized the treat-
ment of RCC [10,11]. Although mammalian target of
rapamycin (mTOR) inhibitor was not available in
Japan at the time of this study, the efficacies of mTOR
inhibitors have been reported [12,13]. These develop-
ments have made it necessary to predict the prognosis
of individual patients with advanced RCC and to select
optimal management. Many clinical risk factors have
been proposed, and classifications of patients using
these risk factors have been established. The most
common classification was proposed by the Memorial
Sloan-Kettering Cancer Center group for cytokine-
based therapies (MSKCC classification)[14], and modi-
fied criteria adapted for the new era of molecular
targeting was reported recently and recommended in
the National Comprehensive Cancer Network guideline
(NCCN classification)[12,15]. However, these classifica-
tions are not enough to determine the best treatment
selection for an individual patient. Novel biomarkers to
predict the prognosis of individual patients are there-
fore desired.
During the last decade, 18-fluoro-2-deoxy-D-glucose
positron emission tomography (
18F-FDG-PET) emerged
as a useful non-invasive tool to evaluate the metabolic
status of tumors. Numerous recent studies of various
types of malignancies have reported an association
between the
18F-FDG accumulation rate evaluated by
PET and patient prognosis. The standardized uptake
value (SUV) is a semiquantitative simplified measure-
ment of the tissue FDG accumulation rate, and studies
of the head-and-neck, lung, and cervical cancer have
e x p l o r e dt h ep r o g n o s t i cs i g n i f i c a n c eo ft h em a x i m u m
standardized uptake value (SUVmax) [16-19]. However,
t h er o l eo ft h eS U V m a xa sap r o g n o s t i cf a c t o rf o r
patients with advanced RCC has not yet been evaluated.
In the present study, we evaluated prospectively the
impact of SUVmax on the survival of patients with
advanced RCC.
Methods
Patients
This was a prospective study to clinically follow enrolled
patients planning to undergo systematic therapies for
advanced RCC. In principle, the pathologies of enrolled
cases were confirmed by prior nephrectomy or biopsy,
but only one case was diagnosed clinically by conven-
tional imaging because the patient wished to be treated
immediately and did not consent to biopsy. The patients
were initially assessed by conventional imaging techni-
ques (computed tomography [CT], magnet resonance
imaging [MRI], or bone scintigraphy) and diagnosed as
stage IV or metastatic RCC. Patients with uncontrolled
diabetes mellitus, with other known malignancies and
treated with therapeutics the last 2 weeks before the
scan were excluded.
The study protocol was approved by the Yokohama
City University Institutional Review Board. Written
informed consent was obtained from all patients. The
patients underwent various therapeutic interventions
decided before the evaluation by PET/CT at Yokohama
City University Hospital and Kanagawa Cancer Center.
Imaging
Patients fasted for at least 6 hours prior to intravenous
injection of [
18F] FDG. PET/CT images were obtained
using a PET/CT system (Aquiduo 16; Toshiba Medical
Systems, Tokyo, Japan). PET/CT images were acquired
from the top of the head to the mid thigh at 60 min
after intravenous injection of 2.5 MBq/kg of [
18F] FDG.
A low-dose non-contrasted CT scan was acquired first
a n du s e df o ra t t e n u a t i o nc o r rection. Emission images
were acquired in 3-dimensional mode for 2 min per bed
position. After PET acquisition, CECT was performed
with a 2-mm slice thickness, 120 kV, 400 mA, 0.5 s/
tube rotation, from the top of the head to the mid
thigh, with breath holding. A total of 100 ml contrast
medium (iopamidol) was administered intravenously at
a rate of 1.0 ml/s. The scan delay was set at 120 s after
starting the injection of contrast material. Images were
reconstructed by attenuation-weighted ordered-subset
expectation maximization (OSEM) (four iterations, four-
teen subsets, 128’ 128 matrix, with 5-mm Gaussian
smoothing). The highest SUV in all RCC tumors of each
patient was defined as SUVmax. To obtain the SUVmax,
the SUV values of all lesions in tumors diagnosed as
RCC by CT imaging were analyzed.
Statistical analysis
Survival time was calculated from the date of evaluation
by
18F-FDG PET/CT to the date of death. Cox propor-
tional hazards model was used to assess the effects of
SUVmax on survival. The cancer-specific survival curve
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resulting curves were compared using the log-rank test.
All statistical analyses were carried out with SPSS soft-
ware (SPSS, Inc, Chicago, IL).
Results
Patient characteristics and intervention
A total of 26 patients (21 males and 5 females) were
enrolled in this study between 2008 Jun and 2009
October (Table 1). The median age was 61 years (range
of 32-82). There were 17 patients with recurrent diseases
and 9 with stage IV disease. Pathological examination
showed 18 cases of clear cell carcinoma, 5 of papillary,
and 2 of clear/sarcomatoid; in one case, the pathological
type was unknown. As for prior surgeries, 19 patients
had undergone nephrectomy and 4 metastatectomy.
Thirteen patients had not undergone previous systematic
therapies. Of the other 13 cases with previous systematic
therapies, 9 patients had undergone interferon-alpha
(IFN-a therapies, one sorafenib, one S1, one combined
therapy with IFN-a and sorafenib, and one combined
therapies with IFN-a and UFT.
After the evaluation by PET/CT, 20 patients were
treated with multiple TKIs (9 sorafenib, 9 sunitinib,
2 sequential therapy with sorafenib and sunitinib, and
1 sequential therapy with sorafenib and IFN-a), and
6 patients underwent cytokine therapies. At the follow-
up end (January 2010), there were 9 cases with cancer
death, and we confirmed the other 17 patients alive.
There were no cases with death due to other causes and
no cases dropped out during follow-up. The median fol-
low-up period was 262 days (range, 43 to 531 days).
Accumulation of FDG in the lesions diagnosed as RCC
tumor by CT imaging
We first, examined the FDG accumulation in all 368
tumor lesions in 26 patients who were diagnosed as
stage IV or metastatic RCC by CT imaging. FDG uptake
was detected in 230 of 243 lesions (94.7%) excluding
lung or liver metastasis with diameters less than 1 cm.
On the other hand, among 125 lung or liver lesions
with diameters between 5 mm and 9 mm, FDG accumu-
lations were detected in only 21 lesions (16.8%). The
SUV in RCC lesions demonstrated various values from
Table 1 Characteristics of the 26 patients
Patient
ID
Sex Age Pathology Nephrectomy MSKCC
classification
NCCN
classification
Prior
therapy
SUVmax SUVmax site
type grading
2 M 63 sarc/
clear
3 Yes Poor Poor IFN 15.2 local recurrence
3 M 73 clear 2 Yes Favorable Not Poor IFN IL 8.2 lung
4 M 61 papillary 3 No Intermediate Poor non 8.8 primary
5 F 72 clear 1 No Intermediate Not Poor non 5.2 primary
6 F 55 clear 2 No Intermediate Not Poor IFN IL 6.8 primary
7 M 57 papillary 2 Yes Intermediate Poor N 4.0 bone
8 M 59 clear 2 Yes Intermediate Poor non 7.4 bone
9 M 68 clear 3 Yes Intermediate Not Poor IFN 5.7 bone
10 F 57 clear 2 Yes Poor Poor IFN N 9.1 lymph node
11 M 75 clear 2 Yes Intermediate Not Poor IFN 5.3 muscle
12 M 58 clear 3 Yes Favorable Not Poor IFN 8.5 local recurrence
13 F 61 clear 2 Yes Intermediate Poor IFN C 4.3 pancreas
14 M 59 clear 2 Yes Intermediate Not Poor non 1.4 lung
15 M 61 clear 2 Yes Intermediate Poor IFN 7.7 lymph node
16 M 73 clear 2 No Poor Poor non 16.6 primary
17 F 32 papillary 3 Yes Favorable Not Poor non 16.1 uterus
18 M 56 papillary 2 Yes Intermediate Not Poor C 7.0 lung
19 M 68 clear 2 Yes Intermediate Poor non 9.0 bone
20 M 61 clear 2 Yes Intermediate Not Poor non 5.6 IVC thrombus
21 F 56 sarc/
clear
3 Yes Intermediate Poor IFN 10.0 contralateral
kidney
22 M 62 clear 3 No Poor Poor non 12.0 primary
23 M 61 clear 3 No Poor Poor non 14.3 primary
24 M 82 clear 1 Yes Intermediate Poor non 5.1 bone
25 M 69 papillary 3 Yes Favorable Not Poor non 13.4 lymph node
26 M 66 clear 1 Yes Intermediate Not Poor IFN 8.2 lung
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Page 3 of 8undetectable levels to 16.6. In 6 of 7 patients without
prior nephrectomy, the primary tumor demonstrated
the highest SUV in all RCC tumor lesions (Figure 1),
and lung metastasis showed the highest SUV in another.
In 19 cases with metastases or recurrence after
nephrectomy, bone metastasis demonstrated the highest
SUV in 5 cases, lung metastasis in 4 cases, lymph node
metastases in 3 cases, and local recurrence in 2 cases
(Figure 2). The uterus, pancreas, Inferior Vena Cava
thrombus, muscle metastasis, and contra-lateral kidney
metastasis demonstrated the highest SUV in one case
each.
The impact of SUVmax on patient survival time
We next analyzed the association between SUVmax and
patient survival time. The SUVmax of all patients ran-
ged between 1.4 and 16.6 (mean 8.8 ± 4.0). The patients
with RCC tumors showing high SUVmax tended to
demonstrate poor prognosis, as shown in Figure 1, 2, 3
(26 patients were lined up in order of SUVmax in Figure 3).
When the patient population was subdivided using the
mean SUVmax (8.8), only 2 (13%) of 15 patients with
RCC tumors having an SUVmax less than 8.8 were dead
d u et oc a n c e ra n dt h em e d i a ns u r v i v a lt i m eo ft h e1 5
patients was not calculated because the number of dead
patients was less than half, whereas 7 (64%) of 11 patients
RCC tumors having SUVmax equal to 8.8 or more and
the median survival time of the 11 patients was 156 day
(95% CI 33-279). The survival for these patient subgroups
were significantly different (Figure 4) (P = 0.0012). When
SUVmax was analyzed as a continuous variable, it was
correlated with survival time (P = 0.005 hazard ratio
1.326 95% CI 1.089-1.614).
Discussion
In the present study, we demonstrated that the SUVmax
evaluated by
18F-FDG-PET/CT is a useful predictive
“imaging biomarker” for survival of patients with
SUV max6.8
SUV max14.3
SUVmax 5.2
SUVmax 8.8
Day482
Alive
Day539
Alive
Day129
CD
Day337
CD
6
5
4
23
Patint ID CT PET Fused PET/CT Prognosis
Figure 1 Four Cases with advanced RCC which original sites showed the highest value of SUV among all RCC sites and their
prognosis. The patients with advanced RCCs having high values of SUV max demonstrated poor clinical courses. SUVmax, maximum
standardized uptake value; CT, computed tomography; PET, positron emission tomography; Fused PET/CT, fusion of PET and CT.
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Page 4 of 8advanced RCC. PET has not been generally used for the
screening of RCC due to the urinary excretion of the
radiotracer, which can mask the presence of primary
lesions [20,21]. However the large RCCs often present-
ing in stage IV could be evaluated without the influence
of urinary excretion of the radiotracer by PET/CT pro-
viding combined morphological and functional informa-
tion (Figure 1). In this study, 7 primary RCC lesions,
with diameters ranging from 8.5 cm to 14.7 cm, were
examined by
18F-FDG-PET/CT, and abnormal FDG
accumulations sufficient to evaluate SUV were detected
in all lesions. Pathological diagnosis was confirmed in 6
cases. Distant metastases of RCC could also be detected
without interference of excretory radiotracers. We did
not confirm the pathologies of the individual metastatic
lesions, but the previous report by Majhail et al.w a r -
ranted the accuracy of metastasis diagnosis by
18F-FDG-
PET. They performed biopsy or surgical resection of 36
distant metastatic lesions in 24 patients that were diag-
nosed by
18F-FDG-PET, and pathological findings
revealed metastatic RCC in 33 lesions (89%) [22]. In this
study, FDG accumulation was evaluated in 94.9% of all
RCC lesions diagnosed by CT scan except for lung or
liver metastases less than 1 cm. These results were con-
sistent with a previous report [23] and indicated that
the information gained by
18F-FDG-PET/CT was suffi-
cient to characterize advanced RCCs.
In this era of molecular targeting therapy when var-
ious systematic treatments can be selected, prognostic
biomarkers are required for the purpose of risk-directed
therapy selection. We revealed that the SUVmax has the
potency as a novel biomarker to predict the survival
time of patients with advanced RCC, by multivariate
analyses with standard risk factors or risk classifications.
Day424
Alive
SUVmax 5.7
Day68
CD
SUVmax 9.0
9
19
Patint ID CT PET Fused PET/CT Prognosis
SUVmax 8.2
Day557
Alive 2
1 Day43
CD
SUVmax 13.3
Figure 2 Four Cases with advanced RCC which metastatic sites showed the highest value of SUV among all RCC sites and their
prognosis. A cranial bone metastasis showed the highest SUV among all RCC sites in Patient 9. A metastasis in thoracic vertebra did in Patinet
19. Lung metastases did in Patient 1 and Patient 2. The patients with advanced RCCs having high values of SUV max demonstrated poor clinical
courses. SUVmax, maximum standardized uptake value; CT, computed tomography; PET, positron emission tomography; Fused PET/CT, fusion of
PET and CT.
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Page 5 of 8FDG accumulation is thought to be indicative of the
metabolic activity of a targeted lesion and it has been
found to be a useful index in a variety of cancers. It is
reasonable that a tumor with high metabolism would
show rapid progression and a poor prognosis. It has
been reported recently that
18F-FDG PET/CT is useful
for evaluating the response to sorafenib and sunitinib
treatment of RCC [24,25]. The results showing that
these therapeutics decrease the FDG accumulation of
RCC lesions encourage the hypothesis that the FDG
accumulation is indicative of the biological activity of
RCC. Additionally, it has been reported that intratu-
moral neutrophils were detected in RCCs showing poor
prognosis [26]. SUV may reflect not only the biological
activity of cancer cells but also the presence of migrat-
ing neutrophils.
To our knowledge, this is the first report to evaluate
the impact of SUVmax on survival of patients with
advanced RCC. However, the number of patients and
the follow-up period were limited. Enrollment for this
study continues now, and the impact of SUVmax on the
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Figure 3 The treatments and prognoses of 26 patients lined up in order of SUVmax.
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Page 6 of 8survival of patients with advanced RCC will be more
apparent from results from an expanded number of
patients and follow-up period.
Conclusions
These preliminary data indicate that the SUVmax evalu-
ated by
18F-FDG-PET/CT has an impact on survival in
patients with advanced RCC. Additional study with an
expanded number of patients and period of follow-up is
necessary.
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